Financial Performance - The company's operating revenue for 2024 was ¥153,763,382.65, a decrease of 28.97% compared to ¥216,483,936.65 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥22,410,984.75, down 50.82% from ¥45,565,550.51 in 2023[21]. - The gross profit margin for 2024 was 43.00%, a decline from 47.15% in 2023[21]. - The basic earnings per share for 2024 was ¥0.32, representing a decrease of 52.94% compared to ¥0.68 in 2023[21]. - The weighted average return on equity based on net profit attributable to shareholders was 4.71% in 2024, down from 10.70% in 2023[21]. - The net profit after deducting non-recurring gains and losses was ¥10,912,104.38, a decrease of 70.95% from ¥37,556,891.83 in 2023[21]. - Operating profit for 2024 was ¥28,122,502.40, down 46.84% year-on-year, while net profit was ¥21,874,240.38, reflecting a decline of 50.86%[44]. - The company's revenue for 2024 was reported at ¥153,763,382.65, a slight decrease of 0.16% from the preliminary earnings report[25]. - The net profit attributable to shareholders was ¥22,410,984.75, down 3.66% from the earnings forecast[25]. - Revenue from main business decreased by 28.79% year-on-year, attributed to intensified market competition and reduced market demand[59]. - Net profit decreased by 50.86% year-on-year, mainly due to market competition and declining revenue and gross margin[62]. Assets and Liabilities - Total assets increased to ¥554,443,804.35, representing a growth of 6.23% compared to the end of 2023[23]. - Total liabilities rose significantly to ¥77,859,777.46, marking a 61.51% increase from the previous year[23]. - The company's cash and cash equivalents increased by 33.63% to CNY 121,637,369.29, compared to CNY 91,028,146.11 at the end of 2023[53]. - The company’s long-term equity investments decreased by 45.92% to CNY 6,477,848.66 compared to CNY 11,978,286.90 in 2023[53]. - The company’s accounts payable increased by 44.81% to CNY 38,004,438.25 in 2024[53]. Cash Flow and Investments - Operating cash flow increased by 14.04% to ¥46,103,728.85, indicating improved cash generation capabilities[23]. - The net cash flow from operating activities increased by 14.04% year-on-year to ¥46,103,728.85, primarily due to an increase in government subsidies received[45]. - Deferred income increased by 217.63% year-on-year, primarily due to an increase in government subsidies received during the period[56]. - Total investment decreased by 49.26% year-on-year, indicating a significant reduction in capital expenditures[74]. - The company has raised funds for investment projects based on thorough feasibility studies, but faces uncertainties from market and policy changes[111]. Market and Competition - The company is focused on expanding its market presence and developing new products, although specific details were not disclosed in the report[8]. - The pharmaceutical industry is undergoing significant changes due to government policies aimed at price governance and drug approval reforms, impacting the company's operational environment[46][47]. - The aging population in China is projected to reach 310.31 million by the end of 2024, accounting for 22.0% of the total population, driving demand for healthcare and pharmaceuticals[104]. - The national drug procurement policy has led to an average price reduction of over 50% for 435 drug varieties, promoting a market-driven pricing mechanism[105]. - The market for specialty raw materials is growing, with a notable increase in market share despite competition from bulk raw materials[106]. Research and Development - The company achieved R&D expenditure of ¥8,797,852.61, representing 5.72% of operating revenue, an increase from 4.63% in the previous period[89]. - The total number of R&D personnel decreased to 22, accounting for 5.61% of total employees, down from 8.23%[91]. - The company is in the clinical preparation stage for the new drug "Succinic Acid Doxylamine," aiming for production approval to enhance product quality and market competitiveness[93]. - The company is conducting research on "Calcium Gluconate" to enhance product quality, with ongoing documentation processes[93]. - The company is developing new health food products, including enzyme and selenium-rich series, to increase production and sales[94]. Regulatory and Compliance - The company has obtained various drug production and operation licenses, with the latest expiring in December 2025[180]. - The company is focusing on expanding quality medical resources to county-level hospitals and grassroots healthcare institutions[179]. - The company is actively participating in the supervision of medical insurance funds, with the first batch of social supervisors appointed in November 2024[178]. - The company has implemented a "look back" mechanism for previously inspected medical institutions to ensure compliance[177]. - The company is committed to ensuring nationwide coverage in the medical insurance fund inspection process[177]. Environmental and Social Responsibility - The company has been included in the 2024 Jiangxi Province Green Manufacturing List, reflecting its commitment to environmental protection and sustainable practices[101]. - The company has implemented strict environmental protection measures and updated facilities to comply with national regulations[102]. - The company has established an environmental and safety production team to regularly inspect wastewater treatment[111]. - The company is committed to improving employee skills and standardizing management processes to support sales growth[108]. - The company has established a comprehensive employee welfare system to ensure legal rights and create a harmonious work environment[101]. Shareholder and Governance - The company has established measures to prevent improper control by major shareholders, ensuring fair decision-making processes[110]. - The largest shareholder, Zhang Aijiang, holds 49.19% of the shares, with a total of 34,857,012 shares[139]. - The top ten shareholders collectively hold 52,108,627 shares, representing 73.54% of the total shares[140]. - The company has a total of 70,861,250 shares outstanding, with 58.96% held by controlling shareholders and 41.04% held by other investors[138]. - The company has maintained compliance with its profit distribution policies, ensuring that minority shareholders have opportunities to express their opinions[155].
新赣江(873167) - 2024 Q4 - 年度财报